Sanofi's Breast Cancer Drug Fallout 'Creates Buying Opportunity' For This Stock

Comments
Loading...
  • According to Oppenheimer analyst, the fallout of Sanofi SA's SNY amcenestrant creates a buying opportunity for Arvinas Inc ARVN 
  • The analyst notes that Arvinas shares were pressured after Sanofi decided to discontinue the development of amcenestrant. 
  • Related: Sanofi Earns Price Target Cut After Stopping Breast Cancer Drug Trial.
  • The analyst reiterated an Outperform rating and $102 price target on Arvinas shares, notes that Arvinas ARV-471 is clinically and mechanistically differentiated from competitors in the oral SERD landscape and that it has shown promising single-agent activity in a challenging Phase 1 study population. 
  • The analyst writes, "upcoming VERITAC data focusing on 200 and 500 mg doses, likely to be presented in December, could position '471 as a viable orally-available alternative to fulvestrant."
  • ARV-471 is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the estrogen receptor for locally advanced or metastatic ER+/HER2- breast cancer.
  • Price Action: ARVN shares closed 11% lower at $46.70 on Wednesday.
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!